Avidity Biosciences (RNA) Stock
Clinical biotech developing RNA medicines for muscle diseases. Here's the price, business snapshot, and what's worth knowing about Avidity Biosciences in June 2026.
Avidity Biosciences (RNA) is a clinical-stage biotechnology company developing antibody–oligonucleotide conjugates (AOCs) to deliver RNA-targeted medicines, primarily for neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy. With a market capitalisation of around US$6.66bn, the company is valued on the promise of its novel delivery platform and early clinical data rather than steady revenues. Investors should understand Avidity’s profile: research and development progress, trial readouts, regulatory milestones and cash runway can move the share price materially. Biotech investing carries binary risks — positive trial results can drive gains, while setbacks or safety concerns can lead to sharp declines. The company may require additional funding over time. This summary is educational and not personalised advice; suitability depends on your circumstances and risk tolerance, and it is sensible to consider independent financial advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Avidity Biosciences' stock with a target price of $72.62, indicating potential growth.
Financial Health
Avidity Biosciences is showing promising revenue and cash flow, indicating healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring RNA
Investment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketBiotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
Published: 17 November 2025
Explore BasketAntiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Published: 16 November 2025
Explore BasketM&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketRNA Stocks (M&A Targets) Could See Premium Valuations
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Published: 27 October 2025
Explore BasketOncology Stocks: Partnership Boom or Bubble Risk?
China's Innovent Biologics and Japan's Takeda Pharmaceutical have signed a multi-billion dollar deal to co-develop advanced cancer therapies. This landmark partnership signals a growing trend of international collaborations, creating potential investment opportunities among other biotech firms specializing in immuno-oncology and antibody-drug conjugates.
Published: 22 October 2025
Explore BasketOrphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: 20 August 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: 11 August 2025
Explore BasketBeyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: 5 August 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: 30 July 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: 29 July 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: 25 July 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: 21 July 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: 11 July 2025
Explore BasketAI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: 17 June 2025
Explore BasketLottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Novel delivery platform
Avidity’s AOC technology aims to improve tissue delivery of RNA medicines, a potential differentiator — though clinical proof is still evolving.
Data-driven catalysts
Clinical trial readouts and regulatory milestones can be major share-price catalysts; outcomes may be binary and cause volatility.
Rare-disease focus
Targeting neuromuscular rare diseases offers high unmet need and potential premium pricing, but small patient populations and regulatory hurdles add risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
